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Abstract
Background: Evidence from clinical trials shows rivaroxaban to be effective for the treatment of deep vein
thrombosis. Switching to rivaroxaban following failure of indirect anticoagulants in deep vein thrombosis has not
been demonstrated in a real-life setting.
Case presentation: A 43-year-old white woman was switched from warfarin to rivaroxaban for the treatment of
thrombosis of her right common femoral vein after saphenectomy. The reason for the switch was due to the
instability of anti-coagulation therapy with vitamin K antagonists over a period of 3 months during which she did
not reach the “therapeutic range” of prothrombin time-international normalized ratio.
The ineffectiveness of the conventional oral anticoagulant was confirmed by persistence of moderate-high values
of fibrin D dimers (780 ng/ml) and by residual vein thrombosis at an ultrasound examination. Objectively, her
right leg appeared to be still edematous and warm and pain was elicited by deep palpation. Rivaroxaban was
administered after warfarin discontinuation (prothrombin time-international normalized ratio = 1.43) at a dosage
of 15 mg every 12 hours for 3 weeks, followed by 20 mg once daily for 3 months. After this period, her objective
symptoms significantly improved, with reduction of edema of her lower limb and pain relief. Her fibrin D dimer
values returned to normal (210 ng/ml). An ultrasound showed recanalization of the obstructed venous segment.
Conclusions: In this case report, a switch to rivaroxaban from warfarin was shown to be effective and safe for
the treatment of postoperative deep vein thrombosis, whereas standard oral anticoagulation therapy, which
required dose adjustments over a period of 3 months, was not able to stabilize the therapeutic range of
prothrombin time-international normalized ratio nor improve our patient’s outcome.
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Background
Anticoagulant therapy is effective for the treatment of
acute venous thromboembolism (VTE): deep vein
thrombosis (DVT) and pulmonary embolism (PE) [1].
For more than half a century, standard anticoagulant
therapy with heparin (mainly subcutaneous low molecu-
lar weight heparin; LMWH) overlapped and followed by
oral vitamin K antagonists (VKAs), such as warfarin,
represented the mainstay recommended by guidelines
worldwide [2]. The combination of LMWH/VKAs given
for ≥3 months is capable of significantly reducing mor-
bidity and mortality, preventing recurrent thrombo-
embolism (RTE) during the acute phase and avoiding
long-term complications such as post-thrombotic syn-
drome (PTS) and secondary pulmonary hypertension
(SPH) after PE [3]. However, one of the major limita-
tions of oral VKAs is the need for laboratory monitoring
by prothrombin time test expressed as the international
normalized ratio (PT-INR). In fact, this parameter must
be kept in a “therapeutic range” of 2 to 3 (target 2.5)
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throughout the entire course of therapy (that is, time in
therapeutic range; TTR), and this goal is achieved by
dose adjustments. Unfortunately, it is not always pos-
sible to obtain optimal values of PT-INR due to several
variables that may interfere with VKAs, such as con-
comitant medications and some foods, making the anti-
coagulant effect unstable and therefore increasing the
risk of failure.
Recently, novel drugs termed “direct oral anticoagu-
lants” (DOACs) have been introduced in clinical prac-
tice, including dabigatran, rivaroxaban, apixaban, and
edoxaban, that were shown to be effective for the treat-
ment of VTE [4–7], and represented an alternative to
VKAs (defined as “indirect oral anticoagulants” [8]).
DOACs have demonstrated the same efficacy and safety
as standard therapy with combined LMWH/warfarin,
but with the advantage of not requiring any laboratory
monitoring with dose adjustments, due to a stable anti-
coagulant effect. In particular, in two clinical studies
conducted in the setting of VTE (proximal DVT and PE)
[5, 6], the efficacy of rivaroxaban was shown to be not
inferior to that of conventional anticoagulant therapy. In
a pooled analysis of the two studies, the drug also
yielded a similar incidence of the main safety outcome
but a significant reduction in the incidence of major
bleeding: hazard ratio 0.54; 95 % confidence interval (CI)
0.37 to 0.79; p = 0.002 [9]. In randomized clinical trials,
rivaroxaban was used for the initial treatment of an
acute thrombotic event with a high dose (15 mg twice
daily) administered for 3 weeks followed by a standard
monodose (20 mg once daily) without the support of
LMWH [5, 6]. Yet, in the real-life setting of DVT, no in-
formation is available on the switch to rivaroxaban after
clinical failure with warfarin.
Case presentation
A 43-year-old white woman underwent saphenectomy
(Table 1) of her right lower limb because of severe venous
insufficiency caused by varicose syndrome (Fig. 1). An
ultrasound examination of superficial and deep veins of
her lower limbs carried out before surgery was judged
normal. The surgical intervention of “stripping” was per-
formed using traditional techniques, with no apparent
perioperative complications. Her postoperative course
appeared normal.
Postoperative deep venous thrombosis
Despite all precautions, including early mobilization, on
the fourth postoperative day (Table 1) she experienced a
significant edema of her right lower limb, which appeared
warm and tense. Subjectively, an acute and persistent pain
Table 1 Intervention timeline
Intervention Time point
Saphenectomy Day 0
Edema due to postoperative proximal DVT; start
of anticoagulant therapy (enoxaparin and warfarin)
Day 4
Up to 3 months
Therapy with rivaroxaban Month 4 to 6
DVT deep vein thrombosis
Fig. 1 Varicose syndrome of right lower limb
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was referred. Laboratory tests showed a moderate increase
in leukocytes (15.7 × 103/μl, reference values up to 10 ×
103/μl) and elevated levels of fibrin D dimers (1800 ng/ml;
reference values up to 250 ng/ml). An ultrasound examin-
ation (Philips HD7; 7.5 MHz linear array transducer)
revealed the presence of thrombosis of her common fem-
oral vein in her operated limb (Fig. 2). Diagnosis of post-
operative proximal DVT was made (Table 1).
Anticoagulant therapy
Anticoagulant therapy with enoxaparin at a dosage of
100 IU/Kg subcutaneously every 12 hours was started
overlapped with warfarin at adjusted dosage (Table 1).
Heparin treatment was stopped when her PT-INR
reached values between 2.0 and 2.5. She was discharged
from our hospital with the indication to continue oral
anticoagulants over a period of 3 months and to
perform periodic laboratory monitoring (therapeutic
range of PT-INR 2.0 to 3.0, target 2.5) initially every
week (until optimal PT-INR) and every 3 weeks after-
wards. An appropriate compression by elastic stock-
ings was also prescribed [10].
Instability of conventional anticoagulant therapy
Laboratory tests were periodically performed in order to
monitor the efficacy of oral anticoagulant therapy with
warfarin. Despite frequent dose adjustments, values of
PT-INR in the “therapeutic” range were reached only
once (Fig. 3).
She subjectively presented heaviness and aching of her
right lower limb, which appeared objectively still hot and
swollen with an increased circumference of 0.5 to 2.5 cm
in comparison with her left leg (Fig. 4). Her values of
fibrin D dimers were moderately high (780 ng/ml) and a
residual vein thrombosis was shown by the echoDoppler
(Fig. 5).
Switch to rivaroxaban
Because of the instability of conventional oral anticoagu-
lants and the poor clinical outcome, warfarin was discon-
tinued when her value of PT-INR was 1.43. Rivaroxaban
was started at an intensive dosage of 15 mg every 12 hours
for 3 weeks, followed by 20 mg/day for 3 months (Table 1).
Patient outcome
Three months after the induction of rivaroxaban, she
showed a significant improvement in symptoms, with an
objective evident reduction of edema of her right leg
(Fig. 6), as well as a subjective pain relief with recovery of
walking without interruption. Laboratory monitoring
showed a return to a normal leukocyte count (8.7 ×
103/μl) and fibrin D dimers values (210 ng/ml). An
ultrasound examination confirmed the complete reso-
lution of DVT (Fig. 7).
Fig. 2 Ultrasound image of thrombosis of right common femoral vein
Fig. 3 Instability of prothrombin time-international normalized ratio monitoring during the 3-month period of therapy with warfarin. Orange
highlighted area shows instability range
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Discussion
VTE including DVT and PE is a serious clinical condi-
tion that requires anticoagulants as first-line treatment
[11]. Currently, conventional therapy consists of LMWH
followed by VKAs. Although this approach is effective, it
has some limitations, such as the need for frequent la-
boratory monitoring and, often, difficulty in reaching the
therapeutic range of the PT-INR with consequent insta-
ble anticoagulant effect and poor clinical outcome. The
inadequate management of VTE by standard VKAs may
cause RTE and long-term serious sequelae including
PTS and chronic SPH in case of PE, which represent a
further burden for these patients [11].
When used as monotherapy for VTE, rivaroxaban
showed similar efficacy and safety compared to the
current standard therapy, but without the need for routine
laboratory monitoring [9, 11]. In our patient, the instability
of conventional anticoagulation therapy with combined
LMWH/warfarin as well as the persistence of objective
and subjective symptoms after 3 months of treatment led
us to switch from warfarin to rivaroxaban for a period of 3
more months. Oral rivaroxaban was able to induce
complete resolution of her venous thrombosis, as
shown by clinical, laboratory, and ultrasound imaging
results. Neither bleedings nor renal venous throm-
bosis (RVT) was observed during her entire course of
Fig. 4 Swelling of the right leg compared with left leg after 3-
month period of therapy with warfarin
Fig. 5 Residual thrombosis (circle) of right common femoral vein
after 3-month period of therapy with warfarin
Fig. 6 The right leg compared with the left leg after 3-month therapy
with rivaroxaban
Fig. 7 Ultrasound image of the complete resolution of the right
common femoral vein thrombosis after 3-month therapy with rivaroxaban
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treatment. Conversely, the conventional adjusted ther-
apy with LMWH/warfarin could not stabilize her PT-
INR and did not improve her clinical outcome.
Our patient was switched to rivaroxaban after discon-
tinuation of warfarin, when her PT-INR value was 1.43,
according to recent recommendations, although not evi-
dence based [12]. In fact, to the best of our knowledge,
this is the first example of switching to rivaroxaban in
the treatment of DVT. In fact, this strategy has been in-
vestigated but only in healthy individuals and with re-
gard to the pharmacodynamics and pharmacokinetics
during the transition from warfarin to rivaroxaban [13].
Conclusions
Given the positive outcome, our approach may be consid-
ered in similar clinical situations. In our experience,
switching to rivaroxaban from conventional combined
therapy with LMWH/warfarin was effective and easily
manageable. Neither undesirable side effects nor compli-
cations such as RTE and bleeding occurred throughout
the treatment period. Worth noting, the simple once-daily
oral administration of rivaroxaban improved patient ad-
herence to the extended period of anticoagulant therapy.
Abbreviations
CI: Confidence interval; DOACs: Direct oral anticoagulants; DVT: Deep vein
thrombosis; LMWH: Low molecular weight heparin; PE: Pulmonary embolism;
PT-INR: Prothrombin time test expressed as the international normalized
ratio; PTS: Post-thrombotic syndrome; RTE: Recurrent thromboembolism;
RVT: Renal venous thrombosis; SPH: Secondary pulmonary hypertension;
TTR: Time in therapeutic range; VKAs: Vitamin K antagonists; VTE: Venous
thromboembolism
Acknowledgements
The authors would like to thank Dr Colin Gerard Egan and Dr Clara Ricci
(Primula Multimedia SRL, Pisa, Italy) who provided skillful editorial assistance.
Financial support for editorial services was provided by Bayer HealthCare, Italy.
Funding
Financial support for editorial services was provided by Bayer HealthCare,
Italy. Bayer HealthCare was not involved in the study design, or in the
collection, analysis, and interpretation of data.
Availability of data and materials
No relevant software, database, and raw data besides those reported in the
main text are available.
Authors’ contributions
Both authors participated in the acquisition and interpretation of clinical data
and writing of this case report. Both authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of
this case report and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of this journal.
Received: 9 June 2016 Accepted: 7 September 2016
References
1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein
thrombosis. Lancet. 2012;379:1835–46.
2. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ,
et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–94.
3. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al.
Venous thromboembolism (VTE) in Europe. The number of VTE events and
associated morbidity and mortality. Thromb Haemost. 2007;98:756–64.
4. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al.
Dabigatran versus warfarin in the treatment of acute venous
thromboembolism. N Engl J Med. 2009;361:2342–52.
5. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR,
Decousus H, et al. Oral rivaroxaban for symptomatic venous
thromboembolism. N Engl J Med. 2010;363:2499–510.
6. EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AWA, Decousus H,
Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic
pulmonary embolism. N Engl J Med. 2012;366:1287–97.
7. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M,
Middeldorp S, et al. Edoxaban versus warfarin for the treatment of
symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15.
8. Hillis CM, Crowther MA. Acute phase treatment of VTE: Anticoagulation,
including non-vitamin K antagonist oral anticoagulants. Thromb Haemost.
2015;113:1193–202.
9. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton
TA, et al. Oral rivaroxaban versus standard therapy for the treatment of
symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-
DVT and PE randomized studies. Thromb J. 2013;11:21.
10. Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR, et al.
Compression stockings to prevent post-thrombotic syndrome: a
randomised placebo-controlled trial. Lancet. 2014;383:880–8.
11. Simon McRae. Treatment options for venous thromboembolism: lessons
learnt from clinical trials. Thromb J. 2014;12(1):27.
12 Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and
old anticoagulants, and when and how to switch. Blood. 2012;119:3016–23.
13 Kubitza D, Becka M, Mück W, Krätzschmar J. Pharmacodynamics and
pharmacokinetics during the transition from warfarin to rivaroxaban: a
randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78:353–63.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Schiavoni and Coluccia Journal of Medical Case Reports  (2016) 10:276 Page 5 of 5
